aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis. A total of 17,374 patients, comprising 10,5...
Uložené v:
| Vydané v: | Journal of hepatology Ročník 73; číslo 6; s. 1368 - 1378 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier B.V
01.12.2020
Elsevier Science Ltd |
| Predmet: | |
| ISSN: | 0168-8278, 1600-0641, 1600-0641 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.
A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).
We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin–bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82–0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0–0.8%, 1.5–4.8%, and 8.1–19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7–100% and a negative predictive value of 99.3–100%. The cut-off value of 60 resulted in a specificity of 56.6–95.8% and a positive predictive value of 6.6–15.7%.
This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide.
In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin–bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity.
[Display omitted]
•In total, 17,374 patients with viral and non-viral hepatitis from 11 global prospective cohorts/trials were studied.•An HCC risk score (called the aMAP score, ranging from 0 to 100), which involves only age, male, albumin–bilirubin and platelet data, was developed and validated.•The aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk irrespective of aetiology and ethnicity.•Patients with aMAP score <50, accounting for 44% of overall population, had an HCC incidence of <0.2% per year. |
|---|---|
| AbstractList | Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.
A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).
We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%.
This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide.
In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity. Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.BACKGROUND & AIMSHepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).METHODSA total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%.RESULTSWe developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%.This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide.CONCLUSIONSThis objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide.In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity.LAY SUMMARYIn this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity. Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis. A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686). We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin–bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82–0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0–0.8%, 1.5–4.8%, and 8.1–19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7–100% and a negative predictive value of 99.3–100%. The cut-off value of 60 resulted in a specificity of 56.6–95.8% and a positive predictive value of 6.6–15.7%. This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide. In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin–bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity. [Display omitted] •In total, 17,374 patients with viral and non-viral hepatitis from 11 global prospective cohorts/trials were studied.•An HCC risk score (called the aMAP score, ranging from 0 to 100), which involves only age, male, albumin–bilirubin and platelet data, was developed and validated.•The aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk irrespective of aetiology and ethnicity.•Patients with aMAP score <50, accounting for 44% of overall population, had an HCC incidence of <0.2% per year. Background & Aims Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis. Methods A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686). Results We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin–bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82–0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0–0.8%, 1.5–4.8%, and 8.1–19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7–100% and a negative predictive value of 99.3–100%. The cut-off value of 60 resulted in a specificity of 56.6–95.8% and a positive predictive value of 6.6–15.7%. Conclusions This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide. Lay summary In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin–bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity. |
| Author | Calleja, Jose Luis Flaherty, John F. Buti, Maria Fan, Rong Janssen, Harry L.A. Hou, Jinlin Papatheodoridis, George Lampertico, Pietro Irving, William L. Zhao, Longfeng Zhu, Chaonan Jia, Jidong Shi, Lei Sypsa, Vana Niu, Junqi Lian, Jianqi Wei, Lai Mo, Shuyuan Yasuda, Satoshi Innes, Hamish Suri, Vithika Xie, Qing Lin, Lanjia Dalekos, George Sun, Jian Gaggar, Anuj Barnes, Eleanor Hutchinson, Sharon J. Toyoda, Hidenori Berg, Thomas Zhou, Yuanping Guo, Yabing Idilman, Ramazan Tang, Xiaoping Kumada, Takashi Johnson, Philip J. Hayes, Peter C. Zhang, Zhengang Barclay, Stephen T. Guha, Indra Neil Dou, Xiaoguang Chen, Yongpeng |
| Author_xml | – sequence: 1 givenname: Rong orcidid: 0000-0002-5922-483X surname: Fan fullname: Fan, Rong organization: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China – sequence: 2 givenname: George orcidid: 0000-0002-3518-4060 surname: Papatheodoridis fullname: Papatheodoridis, George organization: Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece – sequence: 3 givenname: Jian orcidid: 0000-0001-5320-227X surname: Sun fullname: Sun, Jian organization: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China – sequence: 4 givenname: Hamish orcidid: 0000-0003-0565-1083 surname: Innes fullname: Innes, Hamish organization: Glasgow Caledonian University, School of Health and Life Sciences, Glasgow, UK – sequence: 5 givenname: Hidenori orcidid: 0000-0002-1652-6168 surname: Toyoda fullname: Toyoda, Hidenori organization: Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan – sequence: 6 givenname: Qing surname: Xie fullname: Xie, Qing organization: Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 7 givenname: Shuyuan orcidid: 0000-0002-8076-358X surname: Mo fullname: Mo, Shuyuan organization: Gilead Sciences, Foster City, CA, USA – sequence: 8 givenname: Vana surname: Sypsa fullname: Sypsa, Vana organization: Department of Hygiene, Epidemiology & Medical Statistics, Medical School of National and Kapodistrian University of Athens, Athens, Greece – sequence: 9 givenname: Indra Neil orcidid: 0000-0002-6940-5861 surname: Guha fullname: Guha, Indra Neil organization: NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK – sequence: 10 givenname: Takashi orcidid: 0000-0003-2211-495X surname: Kumada fullname: Kumada, Takashi organization: Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan – sequence: 11 givenname: Junqi surname: Niu fullname: Niu, Junqi organization: Department of Hepatology, First Hospital, Jilin University, Changchun, China – sequence: 12 givenname: George orcidid: 0000-0001-7075-8464 surname: Dalekos fullname: Dalekos, George organization: Department of Internal Medicine, Thessalia University Medical School, Larissa, Greece – sequence: 13 givenname: Satoshi surname: Yasuda fullname: Yasuda, Satoshi organization: Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan – sequence: 14 givenname: Eleanor orcidid: 0000-0002-0860-0831 surname: Barnes fullname: Barnes, Eleanor organization: Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine and the Oxford NIHR Biomedical Research Centre, Oxford University, Oxford, UK – sequence: 15 givenname: Jianqi surname: Lian fullname: Lian, Jianqi organization: Centers of Infectious Diseases, Tangdu Hospital, the Fourth Military Medical University, Xi'an, China – sequence: 16 givenname: Vithika surname: Suri fullname: Suri, Vithika organization: Gilead Sciences, Foster City, CA, USA – sequence: 17 givenname: Ramazan surname: Idilman fullname: Idilman, Ramazan organization: Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey – sequence: 18 givenname: Stephen T. orcidid: 0000-0003-0415-785X surname: Barclay fullname: Barclay, Stephen T. organization: Glasgow Royal Infirmary, Glasgow, UK – sequence: 19 givenname: Xiaoguang surname: Dou fullname: Dou, Xiaoguang organization: Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China – sequence: 20 givenname: Thomas surname: Berg fullname: Berg, Thomas organization: Division of Hepatology, Clinic and Polyclinic for Gastroenterology, Hepatology Infectious Disease and Pneumology, University Clinic Leipzig, Leipzig, Germany – sequence: 21 givenname: Peter C. surname: Hayes fullname: Hayes, Peter C. organization: Royal Infirmary of Edinburgh, Edinburgh, UK – sequence: 22 givenname: John F. surname: Flaherty fullname: Flaherty, John F. organization: Gilead Sciences, Foster City, CA, USA – sequence: 23 givenname: Yuanping surname: Zhou fullname: Zhou, Yuanping organization: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China – sequence: 24 givenname: Zhengang surname: Zhang fullname: Zhang, Zhengang organization: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 25 givenname: Maria surname: Buti fullname: Buti, Maria organization: Hospital General Universitario Valle Hebron and Ciberehd, Barcelona, Spain – sequence: 26 givenname: Sharon J. surname: Hutchinson fullname: Hutchinson, Sharon J. organization: Glasgow Caledonian University, School of Health and Life Sciences, Glasgow, UK – sequence: 27 givenname: Yabing surname: Guo fullname: Guo, Yabing organization: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China – sequence: 28 givenname: Jose Luis orcidid: 0000-0002-2265-6591 surname: Calleja fullname: Calleja, Jose Luis organization: Hospital U Puerta de Hierro, IDIPHIM CIBERehd, Madrid, Spain – sequence: 29 givenname: Lanjia orcidid: 0000-0001-8174-1748 surname: Lin fullname: Lin, Lanjia organization: Gilead Sciences, Foster City, CA, USA – sequence: 30 givenname: Longfeng surname: Zhao fullname: Zhao, Longfeng organization: Department of Infectious Diseases, First Hospital of Shanxi Medical University, Taiyuan, China – sequence: 31 givenname: Yongpeng surname: Chen fullname: Chen, Yongpeng organization: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China – sequence: 32 givenname: Harry L.A. surname: Janssen fullname: Janssen, Harry L.A. organization: Liver Clinic, Toronto Western & General Hospital, University Health Network, Toronto, ON, Canada – sequence: 33 givenname: Chaonan orcidid: 0000-0001-5031-134X surname: Zhu fullname: Zhu, Chaonan organization: Big Data Research and Biostatistics Center, Hangzhou YITU Healthcare Technology Co. Ltd., Hangzhou, China – sequence: 34 givenname: Lei surname: Shi fullname: Shi, Lei organization: Big Data Research and Biostatistics Center, Hangzhou YITU Healthcare Technology Co. Ltd., Hangzhou, China – sequence: 35 givenname: Xiaoping surname: Tang fullname: Tang, Xiaoping organization: Guangzhou Eighth People's Hospital, Guangzhou, China – sequence: 36 givenname: Anuj surname: Gaggar fullname: Gaggar, Anuj organization: Gilead Sciences, Foster City, CA, USA – sequence: 37 givenname: Lai surname: Wei fullname: Wei, Lai organization: Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China – sequence: 38 givenname: Jidong surname: Jia fullname: Jia, Jidong organization: Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China – sequence: 39 givenname: William L. orcidid: 0000-0002-7268-3168 surname: Irving fullname: Irving, William L. organization: NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK – sequence: 40 givenname: Philip J. surname: Johnson fullname: Johnson, Philip J. email: Philip.Johnson@liverpool.ac.uk organization: Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK – sequence: 41 givenname: Pietro surname: Lampertico fullname: Lampertico, Pietro email: pietro.lampertico@unimi.it organization: Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico - Division of Gastroenterology and Hepatology - CRC ‘A.M. and A. Migliavacca’ Center for Liver Disease, Milan, Italy – sequence: 42 givenname: Jinlin surname: Hou fullname: Hou, Jinlin email: jlhousmu@163.com organization: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32707225$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtv1DAURi1URKeFP8ACWWLTTcK183CC2FQVL6lVWdC1e3FuNE6TONhOUf89HqbdzKKs7MU59_WdsKPZzcTYWwG5AFF_GPJhS0suQUIOKgdZvWAbUQNkUJfiiG0S1GSNVM0xOwlhAIAC2vIVOy6kAiVltWG3eHX-g3sb7ngwzhNfPHXWxMBTaYzO0DiuI3pu0Bs7uwl5R_c0umWiOXI780TZ9A38j41bbrbezdbsbRtteM1e9jgGevP4nrKbL59_XnzLLq-_fr84v8xMqdqYVWhkW5eEAsq6rxBEVzRtX2BbITa1aJu-L0yFdY9SdaUyKHqlKpStAtOVRXHKzvZ1F-9-rxSinmzYTY8zuTVoWUqVOjRCJPT9ATq41c9pukS1RepWg0zUu0dq_TVRpxdvJ_QP-ul2CWj2gPEuBE-9Njampd0cPdpRC9C7mPSgdzHpXUwalIZ_qjxQn6o_K33aS5TOeG_J62DS5U3Ky5OJunP2ef3jgW5Gm6LC8Y4e_if_BQpXvyQ |
| CitedBy_id | crossref_primary_10_1053_j_gastro_2024_11_014 crossref_primary_10_2147_JHC_S292139 crossref_primary_10_1016_j_cgh_2023_04_019 crossref_primary_10_7717_peerj_19712 crossref_primary_10_1002_jmv_70395 crossref_primary_10_1016_j_jhep_2023_05_042 crossref_primary_10_2147_IJGM_S343457 crossref_primary_10_7717_peerj_19150 crossref_primary_10_3390_jcm10020353 crossref_primary_10_1111_apt_17088 crossref_primary_10_1055_a_2189_6353 crossref_primary_10_1111_jgh_16248 crossref_primary_10_1080_14737140_2025_2467184 crossref_primary_10_1111_apt_18291 crossref_primary_10_1111_1744_9987_14003 crossref_primary_10_2147_ITT_S446545 crossref_primary_10_1016_j_gastre_2023_01_008 crossref_primary_10_3389_fonc_2021_762662 crossref_primary_10_1038_s44276_025_00126_5 crossref_primary_10_1111_jvh_13829 crossref_primary_10_1016_j_cgh_2021_05_062 crossref_primary_10_1159_000539371 crossref_primary_10_3389_fcimb_2023_1151899 crossref_primary_10_1002_jmv_29723 crossref_primary_10_1016_j_jceh_2024_102381 crossref_primary_10_1093_bjr_tqaf123 crossref_primary_10_1159_000546574 crossref_primary_10_1016_j_jhep_2021_01_005 crossref_primary_10_1016_j_gastre_2024_04_032 crossref_primary_10_1111_jvh_13717 crossref_primary_10_3748_wjg_v27_i40_6737 crossref_primary_10_3390_diagnostics14131325 crossref_primary_10_1186_s12885_025_14578_y crossref_primary_10_3390_cancers17061018 crossref_primary_10_1002_hep_32779 crossref_primary_10_1002_ueg2_12571 crossref_primary_10_3389_fonc_2025_1570896 crossref_primary_10_1016_j_jhep_2020_10_016 crossref_primary_10_1016_j_jhep_2023_05_039 crossref_primary_10_3390_diagnostics15030252 crossref_primary_10_1111_apt_17658 crossref_primary_10_1186_s12885_024_13185_7 crossref_primary_10_1016_j_jhep_2022_11_003 crossref_primary_10_1080_14737159_2023_2292642 crossref_primary_10_1093_gastro_goaf045 crossref_primary_10_1016_j_jhep_2020_10_008 crossref_primary_10_1111_jvh_70021 crossref_primary_10_1016_j_gastrohep_2023_08_008 crossref_primary_10_1111_jgh_16334 crossref_primary_10_1016_j_jhep_2024_09_020 crossref_primary_10_3389_fimmu_2020_613946 crossref_primary_10_12998_wjcc_v11_i22_5204 crossref_primary_10_1002_jcla_24296 crossref_primary_10_3389_fonc_2022_1037742 crossref_primary_10_1111_jgh_16727 crossref_primary_10_1002_INMD_20240134 crossref_primary_10_1159_000530987 crossref_primary_10_3389_fonc_2022_862297 crossref_primary_10_1038_s41575_024_00967_4 crossref_primary_10_1186_s12889_024_20025_7 crossref_primary_10_1016_j_clinre_2022_102043 crossref_primary_10_1159_000533585 crossref_primary_10_3390_cells10113091 crossref_primary_10_1016_j_biopha_2023_115028 crossref_primary_10_1093_infdis_jiab597 crossref_primary_10_1111_apt_18488 crossref_primary_10_1002_jmv_29884 crossref_primary_10_4103_sjg_sjg_333_23 crossref_primary_10_1016_j_jhep_2022_07_018 crossref_primary_10_1016_j_jhepr_2024_101227 crossref_primary_10_3390_cancers14205063 crossref_primary_10_1097_HEP_0000000000000339 crossref_primary_10_1002_hep_32341 crossref_primary_10_1097_HEP_0000000000000797 crossref_primary_10_1111_liv_15818 crossref_primary_10_3350_cmh_2022_0402 crossref_primary_10_1111_apt_17506 crossref_primary_10_4254_wjh_v16_i1_41 crossref_primary_10_1186_s13027_024_00578_3 crossref_primary_10_7717_peerj_15014 crossref_primary_10_3390_v13071318 crossref_primary_10_1007_s12072_022_10303_0 crossref_primary_10_3390_ijms24054286 crossref_primary_10_3390_diagnostics13010003 crossref_primary_10_14309_ajg_0000000000001897 crossref_primary_10_3389_fphar_2024_1443667 crossref_primary_10_1038_s41467_023_44255_2 crossref_primary_10_1016_j_prp_2022_154136 crossref_primary_10_1111_jgh_16494 crossref_primary_10_1016_j_jhep_2021_11_023 crossref_primary_10_1111_liv_70065 crossref_primary_10_3390_cancers14030828 crossref_primary_10_1016_j_clinre_2022_102050 crossref_primary_10_1002_jmv_28210 crossref_primary_10_2147_JHC_S452628 crossref_primary_10_1007_s00432_023_04911_y crossref_primary_10_1055_a_2189_8567 crossref_primary_10_1016_j_cgh_2025_06_025 crossref_primary_10_1111_apt_17802 crossref_primary_10_1016_j_cgh_2023_02_004 crossref_primary_10_3390_v13071333 crossref_primary_10_1016_j_jhep_2024_04_007 crossref_primary_10_2147_JHC_S505028 crossref_primary_10_1111_jvh_13778 crossref_primary_10_2147_CMAR_S363219 crossref_primary_10_1016_j_apsb_2025_01_017 crossref_primary_10_1080_23744235_2024_2403703 crossref_primary_10_3390_cancers16050887 crossref_primary_10_1111_apt_70360 crossref_primary_10_3390_cancers17142390 crossref_primary_10_3390_microorganisms11122895 crossref_primary_10_2147_JHC_S377435 crossref_primary_10_1007_s12072_023_10567_0 crossref_primary_10_1016_j_clinre_2022_101930 crossref_primary_10_14309_ajg_0000000000001879 crossref_primary_10_1111_liv_15528 crossref_primary_10_1177_20406223221102791 crossref_primary_10_1136_gutjnl_2024_332182 crossref_primary_10_1016_j_metabol_2024_156080 crossref_primary_10_1097_ID9_0000000000000123 crossref_primary_10_1016_j_medcle_2024_07_018 crossref_primary_10_3390_v14091968 crossref_primary_10_1016_j_jhep_2022_12_015 crossref_primary_10_1016_j_cgh_2025_06_005 crossref_primary_10_1111_jgh_70064 crossref_primary_10_1093_jnci_djae304 crossref_primary_10_1007_s10620_022_07731_1 crossref_primary_10_3390_v16121899 crossref_primary_10_1055_a_2460_6298 crossref_primary_10_3390_jcm11092354 crossref_primary_10_1002_hep4_1941 crossref_primary_10_1016_j_cgh_2023_03_024 crossref_primary_10_1016_j_jhep_2023_02_015 crossref_primary_10_1038_s41598_024_83162_4 crossref_primary_10_1016_j_virol_2024_110273 crossref_primary_10_3390_jcm9123843 crossref_primary_10_1007_s00535_025_02270_8 crossref_primary_10_4251_wjgo_v16_i9_3839 crossref_primary_10_3390_jcm11226613 crossref_primary_10_1016_j_jss_2025_06_018 crossref_primary_10_1038_s41598_025_95795_0 crossref_primary_10_1016_j_gastrohep_2023_01_008 crossref_primary_10_14309_ajg_0000000000002827 crossref_primary_10_3390_life13101964 crossref_primary_10_3390_cancers15020544 crossref_primary_10_1111_apt_17139 crossref_primary_10_1016_j_gastha_2022_02_008 crossref_primary_10_1097_HC9_0000000000000618 crossref_primary_10_1097_MD_0000000000040267 crossref_primary_10_1016_j_hlife_2024_06_007 crossref_primary_10_1097_HC9_0000000000000441 crossref_primary_10_1159_000540700 crossref_primary_10_1186_s12985_023_02145_5 crossref_primary_10_1016_j_jhep_2023_05_005 crossref_primary_10_1016_j_jncc_2025_05_005 crossref_primary_10_2196_65286 crossref_primary_10_1016_j_gastha_2021_11_008 crossref_primary_10_1136_gutjnl_2024_332034 crossref_primary_10_1155_2021_9809990 crossref_primary_10_14309_ctg_0000000000000290 crossref_primary_10_1016_j_cgh_2023_03_005 crossref_primary_10_1016_j_cgh_2023_11_005 crossref_primary_10_1016_j_cgh_2024_07_024 crossref_primary_10_1007_s00330_025_11726_7 crossref_primary_10_1016_j_livres_2024_05_004 crossref_primary_10_1055_s_0041_1730924 crossref_primary_10_1002_lci2_41 crossref_primary_10_3390_cancers13102305 crossref_primary_10_1016_j_gastha_2023_07_018 crossref_primary_10_1111_apt_16469 crossref_primary_10_1016_j_hpb_2024_01_001 crossref_primary_10_1111_hepr_13689 crossref_primary_10_1002_lci2_47 crossref_primary_10_1111_apt_18409 crossref_primary_10_3748_wjg_v27_i33_5536 crossref_primary_10_3389_fimmu_2024_1406671 crossref_primary_10_1016_j_ejim_2024_08_018 crossref_primary_10_1186_s12885_023_11628_1 crossref_primary_10_2147_JHC_S495059 crossref_primary_10_1016_j_jhep_2024_04_031 crossref_primary_10_1016_j_jceh_2024_101370 crossref_primary_10_1111_jgh_16673 crossref_primary_10_1111_jvh_14032 crossref_primary_10_3350_cmh_2023_0121 crossref_primary_10_3389_fimmu_2023_1282469 crossref_primary_10_3390_biomedicines11051306 crossref_primary_10_3748_wjg_v31_i34_110602 crossref_primary_10_1097_HEP_0000000000001005 crossref_primary_10_1093_jncics_pkad034 crossref_primary_10_1053_j_gastro_2024_10_035 crossref_primary_10_3390_jcm10153392 crossref_primary_10_3390_jcm13226770 crossref_primary_10_1159_000535497 crossref_primary_10_3390_jcm10050903 crossref_primary_10_3389_fmed_2021_677920 crossref_primary_10_1016_j_jhep_2021_02_018 crossref_primary_10_1186_s12876_023_02900_6 crossref_primary_10_1016_j_antiviral_2024_105892 crossref_primary_10_1016_j_jceh_2025_103183 crossref_primary_10_1177_00033197241228051 crossref_primary_10_2147_JHC_S308587 crossref_primary_10_1016_j_jhep_2020_12_029 crossref_primary_10_1038_s41416_022_01851_1 crossref_primary_10_3389_fimmu_2022_1001506 crossref_primary_10_1159_000530495 crossref_primary_10_1016_j_jhep_2024_08_028 crossref_primary_10_1002_INMD_20230056 crossref_primary_10_1186_s12885_025_13690_3 crossref_primary_10_3389_fonc_2024_1397505 crossref_primary_10_5009_gnl250187 crossref_primary_10_2147_JHC_S357380 crossref_primary_10_1016_j_jhep_2025_09_005 crossref_primary_10_1111_apt_17699 crossref_primary_10_1111_jgh_16416 crossref_primary_10_3350_cmh_2023_0106 crossref_primary_10_1002_ygh2_443 crossref_primary_10_1111_jvh_13884 crossref_primary_10_12998_wjcc_v11_i22_5198 crossref_primary_10_1111_apt_70195 |
| Cites_doi | 10.1016/j.jhep.2014.08.045 10.1053/j.gastro.2008.02.013 10.1053/bega.2000.0143 10.1016/j.cgh.2019.07.010 10.1200/JCO.2014.57.9151 10.1016/j.jhep.2017.11.039 10.1016/j.jhep.2017.07.033 10.1158/1078-0432.CCR-04-0713 10.1111/j.1440-1746.2007.05054.x 10.1111/jgh.13250 10.1016/S1470-2045(11)70077-8 10.1016/j.jhep.2018.07.024 10.3748/wjg.v25.i13.1550 10.1056/NEJMra1713263 10.1016/j.jhep.2013.09.029 10.1016/j.jhep.2016.09.008 10.1111/liv.14155 10.1016/j.jhep.2017.10.033 10.1016/j.cgh.2008.08.005 10.1016/j.jhep.2019.05.008 10.1200/JCO.2009.26.2675 10.1016/j.jhep.2015.11.035 |
| ContentType | Journal Article |
| Copyright | 2020 European Association for the Study of the Liver Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. Dec 2020 |
| Copyright_xml | – notice: 2020 European Association for the Study of the Liver – notice: Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. Dec 2020 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
| DOI | 10.1016/j.jhep.2020.07.025 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0641 |
| EndPage | 1378 |
| ExternalDocumentID | 32707225 10_1016_j_jhep_2020_07_025 S0168827820304785 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Department of Health – fundername: MRF_ grantid: MRF-054-0001-F-INNE-C0825 – fundername: Medical Research Council grantid: MR/K010239/1 – fundername: Cancer Research UK grantid: 29725 – fundername: Medical Research Council grantid: MR/K01532X/1 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW LCYCR RIG 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
| ID | FETCH-LOGICAL-c479t-5ac2964ea1046f5a01d389f3a95aa86198ff3c5a6fa27d47ca1f775a2970cd433 |
| ISICitedReferencesCount | 258 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000590263100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0168-8278 1600-0641 |
| IngestDate | Thu Oct 02 10:24:51 EDT 2025 Fri Jul 25 03:02:49 EDT 2025 Mon Jul 21 06:06:38 EDT 2025 Sat Nov 29 07:22:15 EST 2025 Tue Nov 18 21:59:35 EST 2025 Fri Feb 23 02:44:41 EST 2024 Tue Oct 14 19:36:21 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | HCC Risk score Hepatitis B virus Hepatitis C virus Non-alcoholic fatty liver disease |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c479t-5ac2964ea1046f5a01d389f3a95aa86198ff3c5a6fa27d47ca1f775a2970cd433 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-3518-4060 0000-0001-7075-8464 0000-0001-5031-134X 0000-0003-0415-785X 0000-0002-1652-6168 0000-0002-6940-5861 0000-0003-2211-495X 0000-0002-8076-358X 0000-0001-5320-227X 0000-0001-8174-1748 0000-0002-7268-3168 0000-0002-2265-6591 0000-0002-0860-0831 0000-0003-0565-1083 0000-0002-5922-483X |
| OpenAccessLink | https://dx.doi.org/10.1016/j.jhep.2020.07.025 |
| PMID | 32707225 |
| PQID | 2493861602 |
| PQPubID | 2047556 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2427296811 proquest_journals_2493861602 pubmed_primary_32707225 crossref_citationtrail_10_1016_j_jhep_2020_07_025 crossref_primary_10_1016_j_jhep_2020_07_025 elsevier_sciencedirect_doi_10_1016_j_jhep_2020_07_025 elsevier_clinicalkey_doi_10_1016_j_jhep_2020_07_025 |
| PublicationCentury | 2000 |
| PublicationDate | December 2020 2020-12-00 20201201 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: December 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Amsterdam |
| PublicationTitle | Journal of hepatology |
| PublicationTitleAlternate | J Hepatol |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V Elsevier Science Ltd |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd |
| References | Villanueva (bib5) 2019; 380 Marcellin, Wong, Sievert, Buggisch, Petersen, Flisiak (bib16) 2019; 39 Hou, Zhao, Lee, Hann, Peng, Tanwandee (bib14) 2020; 18 Sharma, Kowgier, Hansen, Brouwer, Maan, Wong (bib13) 2018; 68 Innes, Barclay, Hayes, Fraser, Dillon, Stanley (bib18) 2018; 68 Ioannou, Green, Kerr, Berry (bib12) 2019; 71 Ioannou, Green, Beste, Mun, Kerr, Berry (bib10) 2018; 69 Johnson, Berhane, Kagebayashi, Satomura, Teng, Reeves (bib19) 2015; 33 Pinato, Sharma, Allara, Yen, Arizumi, Kubota (bib24) 2016; 66 Papatheodoridis, Dalekos, Yurdaydin, Buti, Goulis, Arends (bib15) 2015; 62 Ioannou, Perkins, Carithers (bib4) 2008; 134 Llovet, Bruix (bib3) 2000; 14 Agarwal, Brunetto, Seto, Lim, Fung, Marcellin (bib17) 2018; 68 Hiraoka, Kumada, Michitaka, Toyoda, Tada, Ueki (bib23) 2016; 31 Wong, Chan, Wong, Leung, Chan, Ho (bib8) 2014; 60 Camp, Dolled-Filhart, Rimm (bib20) 2004; 10 Nouso, Tanaka, Uematsu, Shiraga, Okamoto, Onishi (bib21) 2008; 23 Harris, Hansen, Gray, Massoud, McGuire, Shoreibah (bib11) 2019; 25 (bib1) 2016 Wong, Chan, Mo, Chan, Loong, Wong (bib7) 2010; 28 Andersson, Salomon, Goldie, Chung (bib22) 2008; 6 Yang, Yuen, Chan, Han, Chen, Kim (bib6) 2011; 12 Papatheodoridis, Dalekos, Sypsa, Yurdaydin, Buti, Goulis (bib9) 2016; 64 (bib2) 2018 Agarwal (10.1016/j.jhep.2020.07.025_bib17) 2018; 68 Hiraoka (10.1016/j.jhep.2020.07.025_bib23) 2016; 31 (10.1016/j.jhep.2020.07.025_bib2) 2018 Harris (10.1016/j.jhep.2020.07.025_bib11) 2019; 25 Andersson (10.1016/j.jhep.2020.07.025_bib22) 2008; 6 Llovet (10.1016/j.jhep.2020.07.025_bib3) 2000; 14 Pinato (10.1016/j.jhep.2020.07.025_bib24) 2016; 66 Wong (10.1016/j.jhep.2020.07.025_bib8) 2014; 60 Papatheodoridis (10.1016/j.jhep.2020.07.025_bib15) 2015; 62 Ioannou (10.1016/j.jhep.2020.07.025_bib10) 2018; 69 Nouso (10.1016/j.jhep.2020.07.025_bib21) 2008; 23 Sharma (10.1016/j.jhep.2020.07.025_bib13) 2018; 68 Villanueva (10.1016/j.jhep.2020.07.025_bib5) 2019; 380 Yang (10.1016/j.jhep.2020.07.025_bib6) 2011; 12 Ioannou (10.1016/j.jhep.2020.07.025_bib4) 2008; 134 Papatheodoridis (10.1016/j.jhep.2020.07.025_bib9) 2016; 64 Johnson (10.1016/j.jhep.2020.07.025_bib19) 2015; 33 Innes (10.1016/j.jhep.2020.07.025_bib18) 2018; 68 Wong (10.1016/j.jhep.2020.07.025_bib7) 2010; 28 Hou (10.1016/j.jhep.2020.07.025_bib14) 2020; 18 Ioannou (10.1016/j.jhep.2020.07.025_bib12) 2019; 71 Marcellin (10.1016/j.jhep.2020.07.025_bib16) 2019; 39 (10.1016/j.jhep.2020.07.025_bib1) 2016 Camp (10.1016/j.jhep.2020.07.025_bib20) 2004; 10 33340577 - J Hepatol. 2021 Apr;74(4):994-996. doi: 10.1016/j.jhep.2020.10.008. 33453325 - J Hepatol. 2021 Apr;74(4):996-997. doi: 10.1016/j.jhep.2021.01.005. |
| References_xml | – volume: 66 start-page: 338 year: 2016 ident: bib24 article-title: The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma publication-title: J Hepatol – volume: 25 start-page: 1550 year: 2019 end-page: 1559 ident: bib11 article-title: Hepatocellular carcinoma surveillance: an evidence-based approach publication-title: World J Gastroenterol – year: 2018 ident: bib2 article-title: Cancer – volume: 12 start-page: 568 year: 2011 end-page: 574 ident: bib6 article-title: Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score publication-title: Lancet Oncol – volume: 14 start-page: 991 year: 2000 end-page: 1008 ident: bib3 article-title: Early diagnosis and treatment of hepatocellular carcinoma publication-title: Baillieres Best Pract Res Clin Gastroenterol – volume: 18 start-page: 457 year: 2020 end-page: 467 ident: bib14 article-title: Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries publication-title: Clin Gastroenterol Hepatol – volume: 68 start-page: 672 year: 2018 end-page: 681 ident: bib17 article-title: 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection publication-title: J Hepatol – volume: 71 start-page: 523 year: 2019 end-page: 533 ident: bib12 article-title: Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification publication-title: J Hepatol – volume: 60 start-page: 339 year: 2014 end-page: 345 ident: bib8 article-title: Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B publication-title: J Hepatol – volume: 64 start-page: 800 year: 2016 end-page: 806 ident: bib9 article-title: PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy publication-title: J Hepatol – volume: 69 start-page: 1088 year: 2018 end-page: 1098 ident: bib10 article-title: Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C publication-title: J Hepatol – volume: 134 start-page: 1342 year: 2008 end-page: 1351 ident: bib4 article-title: Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival publication-title: Gastroenterology – volume: 380 start-page: 1450 year: 2019 end-page: 1462 ident: bib5 article-title: Hepatocellular carcinoma publication-title: N Engl J Med – volume: 62 start-page: 363 year: 2015 end-page: 370 ident: bib15 article-title: Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir publication-title: J Hepatol – volume: 10 start-page: 7252 year: 2004 end-page: 7259 ident: bib20 article-title: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization publication-title: Clin Cancer Res – volume: 6 start-page: 1418 year: 2008 end-page: 1424 ident: bib22 article-title: Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis publication-title: Clin Gastroenterol Hepatol – volume: 33 start-page: 550 year: 2015 end-page: 558 ident: bib19 article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade publication-title: J Clin Oncol – year: 2016 ident: bib1 article-title: Global Health Sector Strategy on Viral Hepatitis 2016-2021 – volume: 68 start-page: 646 year: 2018 end-page: 654 ident: bib18 article-title: The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen publication-title: J Hepatol – volume: 23 start-page: 437 year: 2008 end-page: 444 ident: bib21 article-title: Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances publication-title: J Gastroenterol Hepatol – volume: 31 start-page: 1031 year: 2016 end-page: 1036 ident: bib23 article-title: Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma publication-title: J Gastroenterol Hepatol – volume: 28 start-page: 1660 year: 2010 end-page: 1665 ident: bib7 article-title: Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers publication-title: J Clin Oncol – volume: 68 start-page: 92 year: 2018 end-page: 99 ident: bib13 article-title: Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis publication-title: J Hepatol – volume: 39 start-page: 1868 year: 2019 end-page: 1875 ident: bib16 article-title: Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection publication-title: Liver Int – volume: 62 start-page: 363 year: 2015 ident: 10.1016/j.jhep.2020.07.025_bib15 article-title: Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir publication-title: J Hepatol doi: 10.1016/j.jhep.2014.08.045 – volume: 134 start-page: 1342 year: 2008 ident: 10.1016/j.jhep.2020.07.025_bib4 article-title: Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.02.013 – volume: 14 start-page: 991 year: 2000 ident: 10.1016/j.jhep.2020.07.025_bib3 article-title: Early diagnosis and treatment of hepatocellular carcinoma publication-title: Baillieres Best Pract Res Clin Gastroenterol doi: 10.1053/bega.2000.0143 – volume: 18 start-page: 457 year: 2020 ident: 10.1016/j.jhep.2020.07.025_bib14 article-title: Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2019.07.010 – year: 2018 ident: 10.1016/j.jhep.2020.07.025_bib2 – volume: 33 start-page: 550 year: 2015 ident: 10.1016/j.jhep.2020.07.025_bib19 article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade publication-title: J Clin Oncol doi: 10.1200/JCO.2014.57.9151 – volume: 68 start-page: 672 year: 2018 ident: 10.1016/j.jhep.2020.07.025_bib17 article-title: 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.11.039 – volume: 68 start-page: 92 year: 2018 ident: 10.1016/j.jhep.2020.07.025_bib13 article-title: Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis publication-title: J Hepatol doi: 10.1016/j.jhep.2017.07.033 – volume: 10 start-page: 7252 year: 2004 ident: 10.1016/j.jhep.2020.07.025_bib20 article-title: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0713 – volume: 23 start-page: 437 year: 2008 ident: 10.1016/j.jhep.2020.07.025_bib21 article-title: Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2007.05054.x – volume: 31 start-page: 1031 year: 2016 ident: 10.1016/j.jhep.2020.07.025_bib23 article-title: Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13250 – volume: 12 start-page: 568 year: 2011 ident: 10.1016/j.jhep.2020.07.025_bib6 article-title: Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70077-8 – volume: 69 start-page: 1088 year: 2018 ident: 10.1016/j.jhep.2020.07.025_bib10 article-title: Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C publication-title: J Hepatol doi: 10.1016/j.jhep.2018.07.024 – volume: 25 start-page: 1550 year: 2019 ident: 10.1016/j.jhep.2020.07.025_bib11 article-title: Hepatocellular carcinoma surveillance: an evidence-based approach publication-title: World J Gastroenterol doi: 10.3748/wjg.v25.i13.1550 – year: 2016 ident: 10.1016/j.jhep.2020.07.025_bib1 – volume: 380 start-page: 1450 year: 2019 ident: 10.1016/j.jhep.2020.07.025_bib5 article-title: Hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMra1713263 – volume: 60 start-page: 339 year: 2014 ident: 10.1016/j.jhep.2020.07.025_bib8 article-title: Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B publication-title: J Hepatol doi: 10.1016/j.jhep.2013.09.029 – volume: 66 start-page: 338 year: 2016 ident: 10.1016/j.jhep.2020.07.025_bib24 article-title: The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2016.09.008 – volume: 39 start-page: 1868 year: 2019 ident: 10.1016/j.jhep.2020.07.025_bib16 article-title: Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection publication-title: Liver Int doi: 10.1111/liv.14155 – volume: 68 start-page: 646 year: 2018 ident: 10.1016/j.jhep.2020.07.025_bib18 article-title: The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen publication-title: J Hepatol doi: 10.1016/j.jhep.2017.10.033 – volume: 6 start-page: 1418 year: 2008 ident: 10.1016/j.jhep.2020.07.025_bib22 article-title: Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2008.08.005 – volume: 71 start-page: 523 year: 2019 ident: 10.1016/j.jhep.2020.07.025_bib12 article-title: Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification publication-title: J Hepatol doi: 10.1016/j.jhep.2019.05.008 – volume: 28 start-page: 1660 year: 2010 ident: 10.1016/j.jhep.2020.07.025_bib7 article-title: Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.2675 – volume: 64 start-page: 800 year: 2016 ident: 10.1016/j.jhep.2020.07.025_bib9 article-title: PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy publication-title: J Hepatol doi: 10.1016/j.jhep.2015.11.035 – reference: 33340577 - J Hepatol. 2021 Apr;74(4):994-996. doi: 10.1016/j.jhep.2020.10.008. – reference: 33453325 - J Hepatol. 2021 Apr;74(4):996-997. doi: 10.1016/j.jhep.2021.01.005. |
| SSID | ssj0003094 |
| Score | 2.696423 |
| Snippet | Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a... Background & Aims Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1368 |
| SubjectTerms | Albumin Antiviral Agents - therapeutic use Asian People - statistics & numerical data Bilirubin Bilirubin - analysis Blood Platelets - pathology Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - etiology Cirrhosis Clinical trials Collaboration Ethnicity Female Global Health - statistics & numerical data HCC Hepatitis Hepatitis B Hepatitis B virus Hepatitis C Hepatitis C virus Hepatitis, Chronic - blood Hepatitis, Chronic - complications Hepatitis, Chronic - diagnosis Hepatitis, Chronic - ethnology Hepatocellular carcinoma Humans Interferon Liver cancer Liver cirrhosis Liver Neoplasms - blood Liver Neoplasms - diagnosis Liver Neoplasms - epidemiology Liver Neoplasms - etiology Male Middle Aged Minority & ethnic groups Non-alcoholic fatty liver disease Platelets Predictive Value of Tests Prognosis Risk Assessment - methods Risk Factors Risk score Serum Albumin - analysis White People - statistics & numerical data |
| Title | aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168827820304785 https://dx.doi.org/10.1016/j.jhep.2020.07.025 https://www.ncbi.nlm.nih.gov/pubmed/32707225 https://www.proquest.com/docview/2493861602 https://www.proquest.com/docview/2427296811 |
| Volume | 73 |
| WOSCitedRecordID | wos000590263100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1600-0641 dateEnd: 20210630 omitProxy: false ssIdentifier: ssj0003094 issn: 0168-8278 databaseCode: AIEXJ dateStart: 20200301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DSFeEN8UxmQkxAtKlcRJnDxWqNVAXdlDJ-XNOI6jtRpJ13XT_oH939zFTpoBHeOBl6hyffnw_Xx3tu-DkA-FziI3iSOw3GCSB7AgcDJf5Y7Lkwz0rYwKXeeZnfDpNE7T5LjXu2liYa7OeFnG19fJ8r-yGtqA2Rg6-w_sbm8KDfAbmA5XYDtc78V4eTQ8Nh7jF5iiErMA5HN02TgFzbOucKe-dj1VWEWorH7IJnCqdgvYpFq1cW_KZM811JgAaYs5a-7e3aMf2yOmyirH-qAKKyBrWAqv5vm8sym_OZsysSJd0Ja2msChBEyedrcp_K7Lh5GsEYawRybL1UD_oc2KY1PZxMKuK1s9Zgrw_Cb0zf7DYrCALx3gs-t0rCae-naG7ek3MT6ZTMRslM4-Ls8dLD6Gh_S2EssO2fN5mIBw3Bt-GaVfW5XO3LqiZvu-NvrKOAr--thtFs62FUxtycyekMeWZ3RooPOU9HT5jDw8sk4Wz8l3RBBFBNEaQbRBEL2NINoiiHYQROclbRBEEUHUIoi2CHpBTsaj2edDxxbicFTAk7UTSoWn81qiQ0ARStfLwc4tmExCKWNYgsdFwVQIE1v6PA-4kl7BeSj9hLsqDxh7SXbLqtSvCc1YHEH3XKsc1IeXyUjHjDEl86DwVMT7xGsGTyibpR6LpZyJxh1xIXDABQ64cLmAAe-TTy3N0uRoubM3a3gimuhj0JcC0HQnVdhSWdvU2Jx_pdtv2C6skLgQfpDAMACa_D553_4NcwgZKEtdXWIfH9a9Uex5ffLKwKX9OOZzl4MifnMP6rfk0WY67pPd9epSvyMP1BWwe3VAdngaH1i4_wSdxtCA |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=aMAP+risk+score+predicts+hepatocellular+carcinoma+development+in+patients+with+chronic+hepatitis&rft.jtitle=Journal+of+hepatology&rft.au=Fan%2C+Rong&rft.au=Papatheodoridis%2C+George&rft.au=Sun%2C+Jian&rft.au=Innes%2C+Hamish&rft.date=2020-12-01&rft.issn=1600-0641&rft.eissn=1600-0641&rft.volume=73&rft.issue=6&rft.spage=1368&rft_id=info:doi/10.1016%2Fj.jhep.2020.07.025&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8278&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8278&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8278&client=summon |